United States Antimony Corp. (NYSEMKT:UAMY) shares advanced 3.23% in last trading session and ended the day at $0.32. UAMY Gross Margin is 3.20% and its has a return on assets of -1.10%. United States Antimony Corp. (NYSEMKT:UAMY) quarterly performance is -3.03%.
United States Antimony Corp. (NYSEMKT:UAMY) reported that it has sold 5,377 tons of zeolite in Q4 of 2015 compared to 3,063 tons in Q4 of 2014, an increase of 75%. During 2015, the Company sold 15,235 tons of zeolite compared to 11,079 sold in 2014, an increase of 37%.
On 05 January, Pfizer Inc. (NYSE:PFE) shares moved up 0.72% and was closed at $32.18. PFE EPS growth in last 5 year was 3.10%. Pfizer Inc. (NYSE:PFE) year to date (YTD) performance is -0.31%.
Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, February 2, 2016. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter 2015 Performance Report, to be issued that morning.
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) shares fell -1.95% in last trading session and ended the day at $6.04. ARIA Gross Margin is 98.30% and its has a return on assets of -30.80%. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) quarterly performance is -6.07%.
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) announced that its Board of Directors has voted unanimously to appoint Paris Panayiotopoulos President and Chief Executive Officer (CEO), effective January 1, 2016. Panayiotopoulos joins ARIAD from his current position of President of EMD Serono, Inc. Panayiotopoulos also has been elected to ARIAD’s Board of Directors. He will succeed Harvey J. Berger, M.D., ARIAD’s founder, chairman and CEO.
Epizyme, Inc. (NASDAQ:EPZM) caters to the Healthcare space. Its weekly performance is -10.95%. On the last day of trading company shares ended up at $15.12. Epizyme, Inc. (NASDAQ:EPZM) distance from 50-day simple moving average (SMA50) is 2.75%.
On 31 December, Epizyme, Inc. (NASDAQ:EPZM) announced that the first patient has been dosed in the phase II study on its pipeline candidate, tazemetostat. The phase II multicenter study will enroll up to 90 patients in three cohorts
Juniper Networks, Inc. (NYSE:JNPR) caters to the Technology space. It has a net profit margin of -7.20% and weekly performance is -0.58%. On the last day of trading company shares ended up at $27.55. Juniper Networks, Inc. (NYSE:JNPR) distance from 50-day simple moving average (SMA50) is -7.03%.
Juniper Networks, Inc. (NYSE:JNPR) was upgraded byVetr from a “buy” rating to a “strong-buy” rating in a report released on Tuesday, Analyst Ratings Network.com reports. The firm currently has a $31.77 price target on the network equipment provider’s stock. Vetr‘s price objective would indicate a potential upside of 15.32% from the stock’s current price.